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Summary  
 
 
Infections arising from multidrug-resistant pathogenic bacteria are spreading rapidly throughout 
the world and threaten to become untreatable. The origins of resistance are numerous and 
complex, but one underlying factor is the capacity of bacteria to rapidly export drugs through the 
intrinsic activity of efflux pumps. In this Review, we describe recent advances that have 
increased our understanding of the structures and molecular mechanisms of multidrug efflux 
pumps in bacteria. Clinical and laboratory data indicate that efflux pumps function not only in 
the drug extrusion process, but also in virulence and the adaptive responses that contribute to 
antimicrobial resistance during infection. The emerging picture of the structure, function and 
regulation of efflux pumps suggests opportunities for countering their activities.  
 
 
 
 
[H1] Introduction 
 
Bacterial antibiotic resistance has numerous origins, and several general mechanisms of adaptive 
responses have been described that give rise to resistant behavior in bacterial populations 1. 
Resistant phenotypes can arise from the boost of intrinsic efflux activity through the 
overexpression, asymmetric accumulation during division or mutation of genes encoding energy-
dependent transporters 2-4. Depending on the antibiotic or toxin challenge, efflux can be the 
fastest acting and most effective resistance mechanism in the bacterial repertoire of stress 
responses. Exposure to antibiotics and other drugs often triggers very complex bacterial reactions 
that involve changes in the level of expression of numerous transporter genes, as seen by 
phenotypic profiling of Escherichia coli 5. These transporters provide several antibiotic efflux 
pathways that can work in a cooperative manner or provide redundant functionality 6,7. 
Currently, six families of bacterial drug efflux pumps have been identified that contribute to the 
efflux pathways. One of these, the ATP-binding cassette family (ABC) directly utilizes ATP as 
the energy source to drive transport. The other five groups are secondary-active transporters that 
are powered by electrochemical energy captured in transmembrane ion gradients; they are the 
major facilitator superfamily (MFS), the multidrug and toxin extrusion (MATE) family, the 
small multidrug resistance (SMR) family, the resistance-nodulation-cell division (RND) 
superfamily and the proteobacterial antimicrobial compound efflux (PACE) family 8,9. Most of 
the efflux families have an early origin and have been sustained during the course of evolution, 
as seen for example in the ubiquity of the MFS, MATE and RND families or superfamilies 
among all domains of life. The efflux machinery is well-tuned to cope with hazardous 
compounds and harmful metabolic waste products of immensely diverse chemical character.  
 
Currently, about 80% of all severe bacterial infections observed clinically are attributed to multi-
drug resistant Gram-negative species 10,11. These bacteria are characterized by a cell envelope 
comprising two membranes that function as a barrier to the entry of drugs and other compounds. 
Tripartite efflux pumps span this envelope to drive the efflux of compounds across this barrier 
(Figure 1). Not all transporters form such assemblies, but the pumps can cooperate as part of a 
system that moves the efflux substrates first into the periplasm and then outward through a 
tripartite machine 6,7. 
 
Advances in structural analyses of the different classes of transporters have recently provided 
unprecedented insight into their detailed function. Investigations of pump expression patterns 
reveal complex regulatory networks at the transcriptional and post-transcriptional level with 
connections to many cellular processes, including central metabolism. Accumulating evidence 
suggest that efflux pumps have much broader functional roles during infection, beyond transport 
of noxious compounds (Box 1). For example, pumps can contribute to bacterial pathogenicity 
through transport of proteinaceous toxins and other virulence factors, as well as having roles in 
cell-to-cell communication and formation of protective biofilms. In addition, efflux pumps play a 
part in lipid transport (in Mycobacteria) and possibly persistence in the presence of antibiotics 12.  
In this Review, we summarize our current understanding of the structures and molecular 
mechanisms of multidrug efflux pumps in bacteria. We discuss their regulation by two 
component systems as well as by transcription and post-transcription factors and explore efflux-
mediated resistance to antibiotics.  
 
[H1]  Molecular mechanisms of multidrug efflux 
 
 
[H2] ATP-binding cassette transporters. 
 
The ABC transporters are functionally diverse and mediate ATP-dependent import or export of 
solutes. Some function as modulators of ion channels 13. The structures of ABC transporters 
reveal transmembrane domains (TMDs) that contain substrate-binding pockets and nucleotide-
binding domains (NBDs) that bind and hydrolyse ATP to drive the transport cycle 14-19. 
 
The ABC exporters can be divided into homo- and heterodimeric groups, with the latter being 
particularly relevant for intrinsic and acquired antibiotic resistance in the Gram-positive bacteria 
(for example, PatAB, LmrCD, BmrCD, EfrCD). Although most homodimeric ABC exporters are 
thought to have two equivalent nucleotide-binding sites, heterodimeric ABC exporters contain a 
degenerate binding site that does not support ATP hydrolysis 20. ATP binding at the degenerate 
site establishes additional contacts across the NBD-NBD dimer interface and prevents the NBD 
dimers from fully separating, a molecular feature that might distinguish the hetero- and 
homodimeric ABC transporters. For the heterodimeric ABC exporter BmrCD, the nucleotide-
binding domains have been shown to be non-equivalent, conferring an intrinsic asymmetry in the 
transporter 21. 
 
The current structural and functional data for both importers and exporters support an 
‘alternating access’ mechanism, whereby the conformation switches states between inward-open, 
occluded and outward-open to translocate substrates across the membrane bilayer (Figure 2A). 
The conformational changes are linked with NBD dimerization and dissociation mediated by 
ATP binding and hydrolysis 22-24.  
 
The bacterial homodimeric MsbA uses its ATPase activity to move the lipopolysaccharide 
precursor lipid A from the cytoplasmic leaflet of the inner membrane to the periplasmic leaflet. 
This catalytic action confers the enzyme with the descriptive title of ‘flippase’. The structures of 
MsbA in defined functional states have been elucidated by cryo-electron microscopy (cryo-EM) 
and enabled the visualization of the transport process 25. In the absence of ATP, the 
lipopolysaccharide can be identified in the transmembrane region of MsbA near the periplasm. In 
the presence of a transition state analogue that mimics ATP hydrolysis (ADP-vanadate), MsbA 
assumes a closed state conformation, but when ADP is present, an inward-facing conformation is 
observed. These structures can be considered as snapshots of the transport process and are 
consistent with the alternative access model. The bacterial ABC transporter McjD exports 
antibacterial peptides, and structural and spectroscopic data support a mechanism whereby a 
binding cavity is transiently opened in the outward-facing conformation causing release of the 
peptide 26. In addition to the conformational changes in ABC exporters facilitated by ATP 
binding and hydrolysis, a role of electrochemical ion gradients in transport has been indicated by 
studies of the bacterial homodimeric ABC exporters LmrA 27 and MsbA 28. By analogy with the 
chemiosmotic coupling of secondary-active transporters, the coupling to electrochemical ion 
gradients most likely imposes directionality on steps in the transport cycle of ABC transporters 
that are not regulated by nucleotide. Thus, although bacterial ABC multidrug exporters share 
proteins motifs and common features, the detailed structural differences might translate into a 
diversity in molecular mechanisms 29. 
 
[H2] Tripartite assemblies involving ABC transporters 
 
In E. coli and other Gram-negative bacteria, the ABC exporter MacB contributes to drug 
resistance and virulence. In those organisms, MacB forms a tripartite assembly with the outer 
membrane protein TolC and the periplasmic partner protein MacA. These pumps drive not only 
the efflux of macrolide antibiotics, but also the transport of outer membrane lipopeptides, 
protoporphyrin, polypeptide virulence factors and lipopolysaccharides. The transport processes 
are coupled to ATP hydrolysis by MacB.  
 
Cryo-EM structures have been obtained for the MacAB-TolC assembly, which consists of a 
TolC homotrimer, six protomers of MacA and a MacB homodimer (Figure 1) 30. The 3:6:2 
stoichiometry of the assembly is consistent with results from biophysical experiments 31, and the 
dimer seen in the crystal structure of MacB homologues 32,33. The assembly may also accept 
some transport substrates from the periplasm. For example, the precursor of one of its substrates, 
the heat-stable enterotoxin II 34, is transported by the Sec machinery into the periplasm, where it 
undergoes maturation and might subsequently enter the MacAB–TolC pump through an opening 
observed in the cryo-EM structure 30,33. For substrates that gain access from the periplasmic side, 
MacB possibly uses an ‘outward-only’ transport mechanism proposed for some ABC 
transporters, whereby the substrate-binding pocket remains in an outward-facing state. The 
transporters may intercept their substrates from in an outward-facing binding pocket, then 
undergo a conformational change that is coupled to ATP hydrolysis that decreases affinity for the 
ligand so that it is displaced into the exterior compartment 35,36.  
 
 
[H2] Transporters of the major facilitator superfamily. 
 
The MFS group is found in all domains of life and is the largest and most diverse family of 
transporters. The group encompasses ‘uniporters’ (that move substrates across the lipid bilayer 
without any coupling ions), ‘symporters’ (that couple transport with ion-transport in the same 
direction as substrate) and ‘antiporters’ (that facilitate the movement of ion and substrates in 
opposite directions). Most members of this superfamily function as single, monomeric units. 
They range from 400–600 amino acid residues in length and possess 12 or 14 transmembrane  
helices (TMH) organized as two domains, each of which is composed of bundles of six helices 
(referred to as the MFS fold) 37. The available structural data support an ‘alternating access’ 
mechanism for the MFS proteins, whereby the two domains undergo a conformational switch 
between inward-open and outward-open states during a transport cycle, similar to that described 
above for ABC transporters. Data for the lactose permease symporter LacY show that the 
conformational switch for alternating access is triggered by induced fit from ligand binding, and 
that the electrochemical proton gradients controls the rate of transport 38. The key element of the 
model is that the binding of proton and substrate are ordered, and that a ternary complex is 
formed (Figure 2b). For various MFS transporters, the sequence of binding (that is, proton 
binding followed by substrate binding, or substrate binding followed by proton binding) is 
different.   
  
Multidrug efflux is conferred by members of the drug:H+ antiporters-1 (DHA1) and DHA2 
families. The crystal structures of DHA1 proteins from E. coli have been determined in outward-
open (YajR), occluded (EmrD) and inward-open (MdfA) conformations 39-41. The structural 
gallery of three different conformational states resembles closely the states captured for the 
symporters lactose permease LacY and XylE  38,42,43. The common structural architecture of the 
DHA1 group comprises amino-terminal- and carboxy-terminal domains that are linked by a long 
cytoplasmic amphipathic helix-containing loop. In the substrate-bound structures of MdfA, drugs 
and inhibitors bind in a central cavity (formed by TMH1, TMH4, TMH7 and TMH10) (Figure 
4c). DHA2 family homologues, such as YbgG, have similar domain organization to DHA1 
proteins, except that the domains are connected by two V-shaped TMHs 44.  A motif (termed 
motif C) within the TMH5 situated in the interface between the two N-terminal and C-terminal 
bundles could participate with other helices to prevent proton leakage. Two conserved acidic 
residues, E26 and D34, have been identified in motif D of MdfA and those residues were shown 
to be involved in proton transfer 45, although only D34 participates in substrate-binding 40. 
Spectroscopic data suggest that protonation could drive the conformational switch between 
alternating access states in the antiporters MdfA and LmrP 46. Moreover, lipid-protein 
interactions are reported to affect the proton-dependent and substrate-dependent conformational 
dynamics of MFS transporters (and other classes of pumps) 47-49.  
 
The transport cycle of MFS proteins seems to involve ordered binding and release of proton and 
substrate, but the stoichiometry of drug-proton exchange varies between family members50,51. 
Whereas the DHA2 family transporter exchanges two protons with one substrate, regardless of 
whether the transported drug is cationic with one or two charges, MdfA mostly catalyzes efflux 
of electroneutral or monovalent cationic drugs by exchanging a single proton with a single drug 
molecule. MdfA also transports divalent cations with two charged moieties separated by a long 
linker; however, the export of such a cation drug molecule needs two consecutive transport 
cycles 50. MdfA shows an indirect competition mechanism between H+ and substrates   45, 
whereas both direct and indirect mechanisms of competition might be relevant to the case of 
LmrP 51.  
 
Although MFS transporters generally function as monomers, some family members are fusions 
of two homologous but distinct MFS permeases. A recent crystal structure of the plant NRT1.1 
reveals a homodimer and suggests that the protomers might have different affinity modes 52. In 
Gram-negative bacteria, some DHA2 family proteins can form tripartite assemblies with partner 
proteins to directly transport drugs across the entire cell envelope 53.  
 
 
[H2] Multidrug and toxic compound extrusion transporters. 
 
The multidrug and toxic compound extrusion (MATE) transporters can be categorized into the 
NorM, DinF (DNA-damage-inducible protein F) and eukaryotic subfamilies based on their 
amino-acid sequence similarity. Bacterial MATE transporters use transmembrane H+ and/or Na+ 
gradients to drive the efflux of poly-aromatic and cationic drugs. The structures of NorM and 
DinF subfamily members reveal two bundles of six transmembrane helices 54-57 in which the 
topology is distinct from that seen for the MFS transporters 58. There are N-terminal and C-
terminal domains related by pseudo-twofold symmetry that form a V-shaped central cavity open 
to the extracellular space. The structures apparently adopt an outward-open state with the lower 
portion of the central cavity situated about halfway through the membrane bilayer. NorM may 
use an alternative access transport mechanism, as indicated by the proximity of residue pairs in 
vivo 59.  
 
In the structure of Neisseria gonorrhoeae NorM, a drug-binding site has been identified in a 
central cavity situated near the membrane-periplasm interface (Figure 2c; Figure 4d). The 
interaction with the substrate is largely mediated by ionic and H-bonding 56,60. Three key 
residues that are involved in Na+-coordination (corresponding to N. gonorrhoeae NorM Y294, 
E261 and D377) are highly conserved in the NorM and eukaryotic subfamilies and probably 
participate in the transport process 60. Vibrio cholerae NorM can use both H+ and Na+ gradients 
to transport substrates, and an aspartate (residue D371 in V. cholera NorM) has been identified to 
be involved in proton coupling 61. The substrate and cation interact with distinct subsets of amino 
acids and can bind to the protein simultaneously 62; therefore, the coupling between the fluxes of 
Na+ and drug is likely to be indirect and mediated by protein conformational changes. As the 
drug-binding pocket is proximal to the periplasmic side and is inaccessible in a presumptive 
inward-open state, the protein must adopt a different conformation to recognize substrates from 
the cytoplasmic side. 
 
For the DinF subfamily member DinF-BH, substrates can be deeply bound within the central 
cavity, where the interactions are mostly mediated by hydrophobic amino acids 56,63 (Figure 2c). 
Residue D40 in DinF-BH makes charge-charge interactions with cationic substrates, and 
evidence indicates that protons directly compete with this interaction 63. DinF-BH was also 
captured in an asymmetric outward-open state, in which the pseudo-twofold symmetry is broken 
by the kinking of TMH7 and TMH8 63. For another DinF subfamily member, PfMATE, the drug-
binding site is formed exclusively within the N-terminal domain, and is dominated by polar 
amino acids (Figure 2c). The TMH1 of PfMATE might undergo protonation-dependent bending, 
but its function in the transport cycle and generality to other family members is not clear 56,57.  
 
The currently available structures of MATE transporters are all captured in an outward-facing 
state. The intracellular-facing state may resemble the inward-facing conformation of the 
structurally related MurJ 64, a member of the newly defined supergroup that includes the MATE 
proteins (referred to as the multidrug oligosaccharidyl-lipid polysaccharide (MOP) transporter 
superfamily in the transporter classification database). Having the structure of an intracellular-
facing state with substrate bound would substantially advance our understanding of MATE-
mediated multidrug extrusion. 
 
 
[H2] RND transporters. 
 
The well-characterized Gram-negative members of the RND family include E. coli AcrB, 
Pseudomonas aeruginosa MexB, Neisseria gonorrhoeae MtrD and Campylobacter jejuni CmeB, 
for which high-resolution structures are available 65-70. The RND proteins are relatively large in 
comparison to other bacterial membrane proteins, and the members of this superfamily form 
mainly homotrimers (Figure 3a). The ubiquitous RND superfamily also include members with 
different quaternary structures, such as the monomeric eukaryotic NPC1 71, which is involved in 
cholesterol homeostasis, heterodimeric SecDF, which is part of the protein export complex 72, 
and homodimeric HpnN that shuttles hopanoids to the outer membrane 73. All RND transporters 
have a rather atypical structure for the secondary transporter group and display a conserved 
transmembrane region structure, as well as a periplasmic and luminal domain which comprise up 
to 60% of the mass of the protein. The RND transmembrane domain contains an internal 
structural repeat that originated through a gene duplication event, whereas the fold of the 
periplasmic luminal domain can differ substantially amongst the RND homologs.  
 
Aside from their physiological relevance to the conferment of antibiotic resistance, the molecular 
mechanism of drug poly-specificity, the movement of the drug through the protein, the coupling 
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of proton and drug antiport (that is, energy transduction), as well as the dynamics of the 
assembly and disassembly of the Gram-negative tripartite systems are the most prominent 
questions. The bacterial RND protomer is central to these questions and comprises three larger 
domains: the transmembrane domain, the pore domain and the docking domain that engages a 
periplasmic partner in cases when the RND protein is part of a tripartite assembly (Figure 1). The 
transmembrane domain consists of 12 α-helices, and is the conduit for proton movement, which 
is coupled to drug efflux in the pore domain 67,74-76. The pore domain is the main location of drug 
entry and consists of the subdomains PN1 and PN2, which extend into the periplasm (between 
TMH1 and TMH2), and PC1 and PC2 (which lie between TMH 7 and TMH8) 67,74 (Figure 3a; 
sup info fig 1). These four subdomains form the two main drug-binding cavities: the proximal (or 
access) and distal (or deep binding) pockets. Each is enriched with a variety of aromatic, charged 
and polar residues thought to confer each pocket with slightly different substrate preferences (see 
for example Figure 4a,b). The docking domain consists of the DN and DC subdomains, and its 
interaction with the periplasmic protein will be discussed further in the subsection on the 
tripartite assemblies.  
 
AcrB undergoes marked conformational change upon drug binding. Although the protomers of 
the AcrB trimer are symmetric in the apo state, they have different conformations when actively 
engaged with substrate: the loose (L), tight (T), and open (O) states 74,77. It is thought that these 
conformations represent three states in drug efflux, and that each protomer cycles through these 
states consecutively, with a high degree of cooperativity 4 (Figure 3a, sup info Fig 1). The exact 
details of the process remain to be elucidated, but in brief the model holds that drugs are 
introduced in the L state, move further into the drug binding pocket in the T state, and then are 
extruded into a funnel-shaped ‘canyon’ in the docking domain in the O state 77. The 
conformational changes occur in an apparently strict order, with drugs moving further into the 
protein but unable to leak back into the periplasm, and has been called a ‘peristaltic’ mechanism 
in analogy to the physical process 77. The movements between the PN2 and PC1 subdomains in 
the L to T transition constitute the opening and closing of the distal binding pocket, whereas the 
PN1 and PC2 subdomains seem to move as a rigid body 76. The relative movement of the PN2 
and PC1 and PN1 and PC2 subdomains in the T to O transition closes the periplasmic entry 
pathway and as such prevents the reverse flow of drugs to the periplasm. The intrinsic and 
asymmetric inter-protomer interaction of the PN1 and PN2 subdomains supports the consecutive 
and cooperative drug transport model which is also found consistent with functional 
dependencies of the protomers in the heterotrimeric E. coli MdtBC pump 78. It is therefore a 
surprising finding that the three protomers of the C. jejuni homologue CmeB seem to undergo 
conformational switches independently during the efflux process in microsecond to second time 
range, as determined by fluorescence energy-transfer measurements 70.  
 
Structures of AcrB bound to different substrates illustrate the surprisingly diverse range of 
compounds that the transporter can efflux 54,66,68,74,76,79-82. These structures show slightly different 
substrate preferences between the proximal and distal binding pockets, possibly also based on the 
substrate size or minimal projection areas 81,83,84, and are thought to represent, at least for the 
high molecular weight substrates, a progression of drug entry into the proximal pocket during the 
L state, and movement of drug into the distal pocket during the L to T transition (Figure 3b). A 
short switch loop is located between the two binding pockets of AcrB that seems to regulate drug 
entry into the distal pocket 66,68.  
 
The distal pocket seems to be a universal binding site for the known AcrB drugs. Its binding site 
consists of mainly Phe, but also Ile, Val, Ala and Asn side chains (Figure 4a). The pocket 
represents a hydrophobic pit and seems to accommodate all the known substrates. Although the 
co-structures show binding of single drugs to this pocket, it is not known whether the pocket 
might bind different (smaller) drugs concomitantly. If so, it might provide one of the 
explanations for the strong cooperativity of drug transport observed 85. Water molecules, also 
found to stabilize the binding of substrates and inhibitors 66,79, have been postulated to be 
involved in drug transport as well by assisting substrate-protein interactions in a way compatible 
with the poly-specificity of AcrB 86. 
 
 
Apart from the periplasmic entry pathway which includes the proximal pocket in the L protomer 
and further transport towards the distal binding pocket, other pathways have been proposed using 
channels or tunnels located at the membrane-periplasmic boundary (Figure 3b). One channel 
leading to the distal binding pocket (-tunnel 1) is preceded by a major groove comprising TMH7, 
TMH8 and TMH9, and in most structures, a dodecylmaltoside molecule is deeply bound inside 
68,87,88 89. Channel 2 is defined by the PC1 and PC2 subdomains in the pore domain and directly 
guides substrates from the periplasm to the proximal pocket. This channel seems to be present in 
both L and T protomers, but the PC1-PC2 cleft seems more closed in the latter protomer. Drugs 
originating from the periplasm are thought to enter AcrB through this channel 50,52,68 . A third 
channel has its entry from within the central cavity formed by the three protomers within the 
trimer 67,68,90. This channel was shown to have a preference for planar, low molecular mass, 
cationic aromatic compounds such as ethidium 90. These substrates are suggested to be directly 
transported to the distal binding pocket, bypassing the proximal binding pocket and the switch 
loop. Other substrates, such as the high molecular weight macrolides, are preferentially taken up 
via channel 2. More channels might be present, as carboxylated drugs (such as β-lactams) bind to 
the TMH1-TMH2 groove 53,69, which does not show a defined channel entrance in any of the 
conformations, but which is close to the entrance of channel 3 90. One hypothesis holds that the 
drug-bound TMH2 moves in different conformational sub-states as a type of ‘elevator 
mechanism’ to deliver the transport substrate to the periplasmic pore domain 69. It is interesting 
to note that an analogous channel for substrate transport has been proposed to occur for the 
HpnN transporter, which shuttles hopanoid molecules to the outer membrane of the Gram-
negative species Burkholderia sp., modifying the fluidity of the outer membrane 73. 
 
The transport substrates for AcrB, MexB and other RND transporters encompass diverse 
compounds that have some lipophilic character but can also harbor moieties that are cationic, 
neutral (chloramphenicol and solvents) or acidic (β-lactams). Can the structural basis for such 
broad poly-specificity be rationalised? A recent study on the differences between the AcrB and 
AcrD binding pockets 91, known to accept preferentially lipophilic and hydrophilic molecules, 
respectively, indicated that besides the higher lipophilicity of the AcrB binding pocket, the distal 
binding pocket in AcrD has a higher hydration tendency, and these water molecules could 
facilitate binding of hydrophilic drugs; a similar effect is seen in Salmonella Typhimurium  AcrB 
by G288D substitution2. Moreover, simulations also indicated that dynamics of the loops found 
especially in the proximal pocket, are different in both proteins and may infer induced fit-like 
binding. The binding of drugs to the pocket of RND transporters shares certain features seen in 
crystallographic studies of MDR pump transcription regulators, such as QacR 92. For those 
regulators, activating ligands bind in a large pocket enriched with aromatic side chains, similar to 
what is seen for the RND transporters. The distal binding pocket of the RND transporters is 
comparatively large, and different ligands prefer different areas of the pocket for binding. 
Transport substrates with hydrophilic groups tend to bind to the region of the pocket that is 
enriched with hydrophilic and charged residues but hydrophobic ligands such as cyclohexane or 
chloramphenicol tend to be excluded in these binding pockets. The general principle that might 
account for poly-specificity is that hydrophobic drugs do not require small, shape-
complementary interaction surfaces in the multidrug transporters or their regulators to form 
favourable interactions, because the ligands are not strongly stabilised in bulk solvent and do not 
require extensive desolvation. By contrast, in case of the RND transporters, many of the 
hydrophobic drugs will most likely reside in the outer leaflet of the inner membrane and enter the 
periplasmic pore domain via the channels (channels 1 and 3). Compounds with hydrophobic 
moieties that are likely to partition spontaneously into the bilayer seem to be good substrates of 
the pump, whereas compounds with hydrophilic side chains are apparently not pumped out 
efficiently 93.  For the amphipathic substrates, side chain interactions might stabilize first contact 
to the channel entrance, and the hydrophobic moieties can exert favourable binding energies to 
small regions of large surfaces, similar to that of the distal binding pocket, so that a broad range 
of ligands are accepted with only small differences in binding free energies 94.   
 
 
[H2] Tripartite assemblies involving RND transporters.  
 
In E. coli, AcrB forms a tripartite assembly, the AcrAB-TolC tripartite efflux pump (Figure 1). 
Homologous RND-based assemblies occur throughout the group of Gram-negative bacteria, and 
the AcrAB-TolC pump shares some similarities with the MacAB-TolC pump. The cryo-EM 
structures of the AcrAB-TolC assembly in the drug transport state reveal that the TolC channel is 
open and is likely to remain open when the pump cycles through three distinct conformations. In 
the context of the complete pump assembly, the AcrB trimer adopts asymmetric LLT, LTT or 
LTO conformations in the presence of transportable ligands 80. As described above, ligand 
binding to AcrB is associated with large conformational changes for both the PN1 and PC2 and 
the PN2 and PC1 structural modules that form the drug-binding pocket 76, but the interfaces 
between TolC and AcrA, and between AcrA and AcrB do not change considerably in the 
different transport states.  
 
In contrast to the drug-bound forms of the pump, in the apo-form TolC is sealed closed, and this 
probably represents a resting state or an early assembly state. A proposed quaternary structural 
switch couples and synchronizes initial binding of ligand with channel opening by long-distance 
communication through allostery 81. Quaternary structural changes in AcrB associated with drug 
binding leads to repacking of  the helical hairpin domains of AcrA into a configuration that can 
optimally fit to the open state of TolC. The structural change of AcrA is critical to seal the gaps 
in the pump, which would otherwise provide a route for substrates to leak into the periplasm. 
These conformational changes are accompanied by a contraction of the pump along the long axis 
in its transport state by nearly 10 Å that must entail a local compression of the periplasm, and 
local curvature of the outer membrane and inner membrane near the portal of AcrB. These 
changes are likely to influence the energetics and kinetics of the transport process. 
 
 
 
[H2] Small multidrug resistance and proteobacterial antimicrobial compound efflux family 
transporters. 
 
The small multidrug resistance (SMR) family proteins confer resistance against quaternary 
ammonium compounds and other lipophilic cations in archaea and bacteria. They are indeed 
small, having only four TMHs, but function as homo- or heterodimers 95 (Figure 1). A 
representative family member is EmrE, and structural analyses of the E. coli protein by X-ray 
crystallography, cryo-EM and NMR reveal an architecture of protomers arranged with 
antiparallel orientation to form an asymmetric dimer 96-98 with the two possible configurations 
occur at roughly equal frequencies 99,100. Four TMHs from each protomer are arranged pairwise 
across the dimer interface. The first three TMHs form a substrate-binding chamber, whereas the 
fourth helix is mainly involved in dimerization interactions. The loop connecting TMH3 and 
TMH4 forms a β-strand structure, which holds TMH4 close to the substrate-binding chamber 96-
98. During the transport process, the pump alternates between inward- and outward-facing states 
through conformational exchange of the two protomers. Therefore, the two states are identical 
except that they have opposite orientation in the membrane 98.  Such global conformational 
motions are modulated in an allosteric fashion by protonation (of E14 in TMH1), which causes 
extensive rotation and tilt of TMH1, TMH2 and TMH3 in conjunction with repacking of loops 
101,102. Substrate property affects the transport rate of the pump, and single residue substitution in 
the drug-binding chamber could change the specificity of SMR pumps 103,104.  
 
Although SMR-like, the Acinetobacter chlorhexidine efflux protein (AceI) has recently been 
identified as a member of a novel family of multidrug efflux pumps termed PACE  9. AceI and 
its homologues were shown to contribute to resistance against various synthetic bactericidal 
agents (chlorhexidine, acriflavine, proflavine and benzalkonium). AceI has a similar size and 
predicted secondary structure to SMR family members and shares the conserved Glu residue in 
TMH1 8. The lack of PACE protein-encoding genes in the E. coli chromosome suggests that 
these genes were lost early after the divergence from other γ-proteobacteria. 
 
 
[H1] Drug efflux pump regulation  
 
 
The association of efflux with drug resistance was first reported nearly four decades ago. To 
confer effective drug resistance, efflux must match or exceed the rates of influx, and this in turn 
depends on the composition of the cell envelope and the access to conduits for drug entry such as 
porins or other routes 4. Indeed, porin loss is one mechanism that can confer resistance and has 
been observed to develop during the course of therapy 4. There have also been numerous 
reported cases of efflux-mediated resistance in clinical isolates (Table 1), some of which are 
associated with overexpression of pumps 105 .  
 
Understanding the regulation of efflux is important as alterations in the regulatory system, such 
as mutations in the local and global transcriptional regulators, lead to overexpression of efflux 
pumps. Efflux regulation can differ between species, and even within a species depending on 
cellular physiological status. The regulation is complex and highly interconnected, and inhibition 
or deletion of one pump can result in expression of others. For example, the deletion of acrB 
results in potentially compensating overproduction of AcrD and AcrF 105. Thus, efflux pump 
networks complicate the interpretation of resistant phenotypes.  
 
[H2] Regulation by two component systems.  
 
Bacteria sense and respond to various environmental stimuli, including stress associated with 
drug action, using two-component systems (TCSs), which contribute to the adaptive responses 
that confer drug resistance (Figure 5). The systems comprise a sensor histidine kinase and 
response regulator, and they can be found in many organisms from all domains of life. The 
histidine kinase and response regulator together function to link signal detection and the 
generation of the appropriate cellular response (Figure 5a). A few studies reported that the 
histidine kinase senses the antibiotic directly through binding , such as VanS, which directly 
interacts with vancomycin 106, but in most cases sensing seems to be indirect. An interesting 
example is provided by the mechanism of bacitracin resistance in Bacillus subtilis: the bacitracin 
efflux ABC transporter BceAB itself functions as the sensor by communicating its transport 
activity to the histidine kinase BceS through protein-protein interaction 107,108. 
 
In terms of molecular organization, the membrane-associated sensor histidine kinase functions 
typically as a homodimer and consists of a sensor module, a transmembrane domain (TMD), and 
one or several intracellular signal transduction domains (such as HAMP, PAS or GAF), as well 
as an intracellular catalytic core, which comprises a dimerization and histidine-phosphotransfer 
(DHp) domain and a catalytic ATP-binding (CA) domain 109,110.  The response regulator protein 
generally contains a conserved N-terminal receiver (REC) domain and a highly diverse C-
terminal effector domain. The response regulator proteins can be divided into five classes 
according to how the effector domain exerts its response, namely DNA-binding, RNA binding, 
enzymatically active, protein-binding and single-domain effector 110.  
Some two component systems, such as CpxAR in Enterobacteriaceae, AdeSR in Acinetobacter 
baumannii and AmgRS in Pseudomonas aeruginosa 111 regulate the expression of multidrug 
resistance efflux pumps. Mutations in adeSR were found in numerous clinical isolates of A. 
baumannii 112 and are associated with overexpression of the RND pump AdeAB 112,113. The 
response regulator component AdeR activates adeABC expression by binding to a direct-repeat 
motif in the intercistronic region 114, and mutations in AdeR lead to enhanced efflux activity of 
AdeB 115. AdeRS not only regulates the expression of the tripartite pump system encoded by 
adeABC, but also genes for biofilm formation and virulence 116. Interestingly, TCSs can regulate 
more than one type of pump, such is the case of BaeSR in A. baumannii, which is proposed to 
indirectly regulate AdeAB and AdeIJK RND efflux pumps and also the MacAB ABC pump, and 
which has been suggested to influence increase resistance to tigecycline. Similarly, in Salmonella 
enterica subsp. enterica serovar Typhimurium BaeSR regulates the expression of AcrD and 
MdtABC RND pumps 117. In E. coli, fifteen TCSs have been identified that contribute to drug 
resistance, five of which modulate the expression of drug efflux pump genes. The E. coli BaeSR 
and CpxAR systems activate the expression of mdtABC and acrD in response to indole and 
envelope stress, respectively. The two-component EvgAS system controls the expression of 
mdtEF, emrKY, acrAB, tolC and mdfA, but the triggering stimuli are currently unknown 4,118. 
Expression of the TolC outer membrane channel is also affected by another two-component 
system, PhoPQ.  
 
Structural and functional data have advanced the mechanistic understanding of TCS systems. 
The crystal structures of E. coli nitrate and/or nitrite sensor histidine kinase NarQ provide a 
direct demonstration of signal transduction through the TMD and HAMP domains 109. Ligand 
binding to the sensor domain causes piston-like shifts of TMHs, which is accompanied by 
extensive rearrangements. The HAMP domain protomers undergo lever-like motions and convert 
the piston-like movements of the TMHs into helical rotations. It is presently unclear how this 
conformational change transduces downstream of the HAMP domain to activate the catalytic 
core. The structure of HK853-RR468 complex from Thermotoga maritima reveals the 
communication between the histidine kinase and response regulator, during which a phosphoryl 
group is transferred from phosphorylated H260 in the HK853 catalytic core to D53 of the 
RR468, and thereby activates RR468 119 (Figure 5a). The signal-activated HK853 auto-
phosphorylates the conserved H260 in the DHp domain. The RR468 dimer docks onto the DHp 
domain and catalyzes its own phosphorylation at D53, using the phosphorylated histidine as a 
substrate. For the DNA-binding response regulator subfamilies, the activated response regulator 
can form a homodimer that binds to a specific DNA-binding motif and activates the transcription 
of target drug transporter gene (Figure 5b). 
 
[H2] Regulation by transcription and post-transcription factors. 
 
Clinical isolates of drug-resistant bacteria have been found to contain genomic mutations in 
transcriptional repressors and in the promoters of the genes encoding RND and ABC 
transporters. Mutations in genes encoding local regulators, such as the TetR family of 
transcriptional [repressors (for example,  emrR, acrR, mtrR) 120-123, or overexpression of global 
transcriptional regulators, including AraC/XylS transcription factors (for example, MarA, SoxS, 
RamA), results in overexpression of efflux pumps and increased transport activity. Although 
rare, 4% of Neisseria gonorrhoeae isolates carry mutations in the mtrA global regulator gene, 
resulting in lack of overexpression of the MtrCDE RND efflux pump 124.  
 
The AcrB RND transporter is encoded in the acrRAB operon, and AcrR functions as the local 
repressor of the operon (Figure 5C). Mutations in acrR lead to overexpression of AcrAB and 
have been described in clinical and veterinary isolates resistant to the AcrB substrate 
fluoroquinolone 4. AcrR is one of many regulators of the operon, examples of other regulators 
are Mar, RamA, Sox and Rob (see below). AcrB overproduction in Klebsiella sp. and Salmonella 
sp. is caused mainly by mutations in ramR and in one case in soxR 4. In the same way in which 
the expression of one pump is controlled by multiple regulators, it has also been shown that one 
regulator can control the expression of multiple pumps. For example, MarA in E. coli regulates 
the expression of AcrAB-TolC and is also involved in regulation of the ABC transporter encoded 
by the mlaFEDCB operon 125. The transcription of acrAB and tolC genes encoding the tripartite 
assembly is controlled by many regulators, including MarA, RamA, SoxS and Rob. These are 
transcription factors that bind to the marbox, a degenerate sequence of approximately 20 base-
pairs found in multiple promoter sequences. These factors can activate the transcription of 
multiple genes, including those encoding efflux pumps and porins. Together, the different 
regulatory mechanisms can give rise to multi-drug resistance by decreasing influx through 
suppression of the expression of the OmpF porin, while increasing efflux mediated by AcrAB-
TolC.  
 
The ArmZ-MexZ system functionally links the activation of the pump with ribosome activity, 
and at least two signal transduction regulatory systems interconnect MexXY-OprM or  MexXY-
OprA with other cellular processes. Transcriptional attenuation is another mechanism that is 
involved in regulating some antibiotic efflux pumps 4. 
 
Post-transcriptional processes are involved in fine-tuning regulation of gene expression and are 
likely to be involved in controlling antibiotic susceptibility and efflux pump expression 126,127. 
The recent discovery of antibiotic-responsive riboswitches from studying changes in RNA levels 
in bacterial communities has highlighted key regulatory role of RNA in the emergence of 
resistance 128. Expression of efflux pumps can be regulated by attenuation through cis-encoded 
RNA elements as primary regulatory mechanism. In these cases, the antibiotics target the 
ribosome and cause stalling when translating a short leader peptide upstream of the resistance 
gene. As a result, RNA secondary structure is changed and the resistance gene can be translated 
or transcribed (depending whether translation or transcription termination is regulated by 
attenuation) 128.  
 
Trans-acting small regulatory RNAs (sRNA) (Figure 5d) are also likely to have important roles 
in efflux regulation, as suggested by the phenotype of strains that are defective for expressing the 
Hfq protein that is a chaperone for sRNAs. Such mutants are not only attenuated in virulence but 
also more susceptible to many antibiotics 123. There are at least three known mechanisms of 
efflux pump regulation by sRNA. In one such case, sRNA can repress translation by blocking the 
ribosome-binding site (RBS) through binding to the latter. sRNA can also promote mRNA 
degradation through its specific binding to a cognate site in the transcript and via recruitment of 
ribonucleases. In addition to its repressor function, sRNsA are able to promote translation 
(activator function) by preventing the formation of inhibitory secondary structure in the target 
mRNA [Au: can you please add a brief description of the regulatory mechanism shown in 
the figure: blocking the ribosome binding site; promoting mRNA degradation through 
specific binding to a cognate site in the transcript; promotion of translation in an activator 
function through prevention of inhibitory secondary structure. OUR REPLY: THE NEW 
TEXT IS HIGHLIGHTED IN YELLOW ABOVE] Some notable examples are the sRNA 
SdsR, which binds and represses the tolC mRNA in E. coli and Salmonella [Au: a specific 
species?] 129 and DsrA which regulates expression of MdtEF, albeit indirectly 130. In Neisseria 
gonorrhoeae, [Au: a specific species? – yes, added] expression of MtrF (a component of 
MtrCDE) is regulated by sRNA NrrF 131. sRNAs can contribute to ‘rewiring’ TCSs and linking 
these with other processes, and can thereby affect the expression of efflux pumps 132. These 
regulatory RNAs can also regulate numerous processes related to virulence 129,130.  In principle, 
compounds that target such riboregulators could affect antibiotic resistance and could be useful 
leads for drug development. 
 
 
[H2] Regulation of AcrB by a small peptide. 
 
Small proteins have been discovered in various organisms that can have important biological 
roles. Often overlooked in genome studies, these small proteins affect spore formation and cell 
division, regulate transport, membrane-bound enzymes, protein kinases and signal transduction, 
and function as chaperones, among other functions 133. There are approximately 60 confirmed 
small proteins in E. coli 134. These proteins are often expressed under specific conditions, and 
many are thought to modify the activity of large membrane proteins 134. 
 
E. coli AcrZ is a 49 amino acid small protein that interacts with and regulates AcrB 134. Deletion 
of acrZ results in sensitivity to some but not all of the antibiotics for which AcrB provides 
resistance 134. This indicates that AcrZ has a role in substrate recognition or AcrB regulation. 
Indeed, AcrB and AcrZ are co-regulated by the transcription factors MarA, Rob and SoxS, 
supporting a key functional role for the small protein 134. Structural studies of the AcrBZ 
complex by X-ray crystallography and in the context of the full pump assembly (by cryoEM) 
indicate that AcrZ forms a helix that interacts with AcrB in the transmembrane portion 80,135. 
Perhaps AcrZ and other related peptides might exercise allosteric effects on their RND partners 
to modulate efflux activities. 
 
[H1] Efflux-mediated resistance to antibiotics.  
 
Whole-genome sequencing case studies suggest that adaptive evolution within the host has an 
important role in bacterial infections 136. Sub-lethal doses of antibiotics can trigger numerous 
processes that enable bacteria to survive antibiotic exposure. Epigenetic effects have been 
proposed to play a part in upregulating efflux transporters. The observed phenomenon of 
persistence, whereby a subpopulation of bacteria that may be metabolically quiescent survives 
initial exposure to antibiotic even though they may be genetically identical compared to the drug-
susceptible group, may complicate strategies for treatment 137,138. It is interesting to note that in 
E. coli, persister cells have been proposed to have enhanced efflux activity and lower 
intracellular antibiotic concentrations 12. The persistent subpopulation might be greater in a 
biofilm 139. Efflux pumps also have a role in the establishment of hetero-resistance, which is 
characterized by subpopulations of bacteria that have a resistant phenotype, conferring clinical 
levels of resistance to the isolate.  
 
In many cases, MDR clinical isolates of bacteria exhibit multiple mechanisms of resistance 4. For 
example, fluoroquinolone-resistant MDR E. coli were found to have increased efflux, decreased 
permeability and a mutation that decreases gyrase sensitivity to the drug (GyrA S83L) 140. 
Similar findings were made for fluoroquinolone-resistant S. enterica serovars  141 and strains of 
M. tuberculosis 142 resistant to quinolones and other drugs. For example, mutations in inhA or 
katG confer resistance to isoniazid in M. tuberculosis 142. 
 
Overexpression of efflux pumps is one mechanism that can contribute to multidrug resistance. 
Redirecting protein synthesis to make efflux pumps is demanding metabolically, so perhaps it 
not surprising that a metabolic cost can be associated with drug resistance 143. Changes in various 
metabolic processes have been observed with overexpression of RND-based pumps in mutants of 
N. gonorrhoeae MtrCDE 144, MexAB and P. aeruginosa MexXY-OprM 145, MexEF-OprN and 
MexCD-OprJ 146. Overexpression of the AcrB RND pump, in response to high concentration of 
chloramphenicol, drives central carbon metabolism from an oxidative state to a fermentative one 
143 and may compensate the stress induced by overexpression 145. In this regard, it is important to 
note that efflux pump gene-deletion mutants may not be the best model to study the 
physiological role of pumps, as there are notable  transcriptome differences between a S. 
Typhimurium ΔacrB and an AcrB D408A mutant 147. The AcrB D408A mutant expresses the 
inactive protein that lacks efflux function (and was found to be attenuated in multiple infection 
models). Importantly there was no increased expression of homologous RND efflux pumps (in 
comparison to the ΔacrB mutant strain). This suggests that the compensatory role of these 
proteins is fulfilling a structural requirement rather than an efflux function. 
 
Although overexpression of pumps might confer drug tolerance, too much overexpression can in 
some cases be detrimental to the fitness and virulence of the bacterium, as seen for instance in a 
S. Typhimurium mutant overexpressing AcrAB 148. Similarly, a P. aeruginosa mutant 
overexpressing MexEF was shown to be less virulent in a Caernorhabditis elegans infection 
model. However, there is no simple rule relating expression and fitness, as shown by the finding 
that a Klebsiella pneumoniae mutant overexpressing AcrAB, via deletion of the transcriptional 
regulator ramR, had increased virulence in a mouse infection model 149. Furthermore, 
overexpression of the MtrCDE RND-based efflux pump in N. gonorrhoeae led to increased 
fitness in a mouse model 144.  
 
Mutations in pumps is a potential mechanism to alter activity, and mutated binding pockets in 
AcrB have been observed to confer clinically relevant MDR that evolved in a patient during 
treatment of an infection by S. Typhimurium. A G288D substitution changed the substrate 
specificity of the pump, conferring ciprofloxacin resistance 2. In drug-resistant clinical isolates of 
Campylobacter jejuni, mutations in the drug-binding pocket of the RND transporter CmeB have 
been identified 150, which map to the corresponding drug binding pocket of AcrB 68,74.  
 
 
  
 
[H1] Conclusions and perspectives 
 
Structural studies of transporters and their assemblies have provided insights into the molecular 
origins of MDR. The mechanisms of the transporters – how they transduce energy to drive 
translocation of substrates – have advanced for the main classes of these proteins. In Gram-
negative species, the transporters function as a coordinated network, in which the final step of 
efflux is achieved by a tripartite assembly. Similar systems are likely to contribute to resistance 
and survival in Mycobacterial pathogens. These advances are complemented by improved 
understanding of the numerous biological roles of pumps beyond simple transport, such as the 
contribution of bacterial efflux pumps towards virulence and community behavior. Future efforts 
to explore the dynamics of pump assembly and the interplay between transporters and transporter 
components, including the regulation of expression of the different components controlled by 
specific regulators, and the identification of antimicrobial targets. Targeting the protein-to-
protein interfaces of the tripartite assemblies might be an efficacious means to counter drug 
tolerance, hence the dynamic process of efflux pump assembly will be an important field to study 
in future (supplementary box 1). Regulators that control the stress response, including RNA-
mediated regulatory networks, may also represent targets to address in future for therapeutic 
intervention.  
 
Comment [Editor2]: Ok to cite the 
suppl. Box here?  YES 
On reflection, the detailed analysis of efflux systems, from the level of stereochemistry to the 
intricate interconnections with physiology and host interactions, illustrates the immense 
complexity of the hidden layers of those biological systems.   
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Table of context 
One factor contributing to the emergence of antimicrobial resistance is the capacity of bacteria 
to rapidly export drugs through the intrinsic activity of efflux pumps. This Review describes 
recent insights into the structure, function and regulation of efflux pumps are described.   
 
 
  
 
TEXT BOX 1  
 
Efflux pumps have diverse biological roles 
 
Molecular genetic studies support the concept that efflux pumps provide an ancient mechanism 
to meet the challenge of surviving in environments laden with noxious compounds. For example, 
Rhizobium etli, a nitrogen-fixating bacterium that forms nodules in roots of Leguminosae, uses 
the RmrAB MFS-based pump to withstand the toxic effects of plant flavonoids 151. Likewise, 
AcrAB, the paradigm RND class pump of the Gram-negative Enterobacteriaceae confers 
resistance to bile salts and so contributes to survival in the mammalian gut 152. Some species, 
such as Pseudomonas sp., have up to a dozen RND pumps, suggesting that it is beneficial for the 
bacterium to have a repertoire of these pumps 153.  
Efflux pumps are required to colonize and disseminate during host infection by many pathogenic 
bacteria and can help bacteria extrude innate host defenses. This is particularly clear in Neisseria, 
which uses RND efflux pumps to extrude host antimicrobial fatty acids and antimicrobial 
peptides. The role of RND pumps in Neisseria sp., Vibrio sp. and Klebsiella pneumoniae in 
export of antimicrobial peptides has been established. For Neisseria gonorrhoeae, the MFS 
efflux pump FarAB is implicated in facilitating rectal infection in mice by ridding the bacteria of 
anti-gonococcal long-chain fatty acids such as linoleic and palmitic acids 154. Salmonella 
enterica mutants of the tripartite assembly AcrAB-TolC have diminished virulence in mice and 
poultry 147,155,156, and deletion of macAB, encoding components of an ABC-type tripartite pump, 
also results in loss of virulence for S. Typhimurium in mice 157.  
In some species, efflux pumps can also actively contribute to infection processes, for example in 
the export of virulence factors, such as siderophores used for the acquisition of iron and other 
required metals. The catechol siderophore vibriobactin is exported by the Vibrio cholerae RND 
pump VexGH 158. Enterobactin, the strongest binding siderophore known, is exported by the E. 
coli MFS transporter EntS, with ‘back-up’ transport function provided by AcrB and other RND 
pumps 159. Group A and B Streptococci internalize heme for chelation of iron 160, but the heme 
itself may then be exported 160. Efflux of heme and protoporphyrins also occur in N. 
gonorrohoeae 161 and E. coli 162. The MATE family member ClbM transports the precursor of 
the toxin colibactin from the cytoplasm to the periplasmic space in E. coli 54. Efflux pump 
activity may in some cases be required for host invasion. Subpopulations of Mycobacterium spp. 
infecting human macrophages showed overexpressed efflux pumps and as a consequence 
increased tolerance to a range of antibiotics 163. Although not identified, the efflux substrate 
might be a host defensive molecule.  
In some bacterial species, efflux pumps can export signaling molecules involved in quorum 
sensing, which is a mechanism of cell-to-cell communication that responds to bacterial 
population density. Quorum sensing controls gene expression at a population level and thereby 
affects colony behavior including virulence and biofilm formation. In the opportunistic pathogen 
P. aeruginosa, the expression of roughly one-tenth of the genome is controlled through quorum 
sensing 164. The sensing signaling molecules acyl-homoserine lactones are exported by the RND 
efflux pump MexAB-OprM 165, and the efflux systems MexGHI and MexEF-OprN export a 
precursor of the Pseudomonas quinolone signaling system 166. Similarly, quorum sensing 
inhibitors based on non-native N-acylated l-homoserine lactones and derivatives are known to be 
exported by MexAB-OprM 167. 
The MexGHI system also exports signaling molecules for biofilm formation (namely, phenazine 
precursors) 168. Inactivation of RND efflux pumps in P. aeruginosa leads to attenuation of 
virulence, presumably due to lack of signaling molecules. Conversely, efflux pump 
overexpression can also lead to an attenuated phenotype because the signaling molecules cannot 
achieve the intracellular concentration threshold required to activate the quorum response as well 
as the potential consequences for cellular energy use 146. 
The AcrB pump has a role in the phenomenon of contact-dependent growth inhibition in E. coli 
that is characterized by the secretion of the toxin CdiA and growth arrest upon inter-cellular 
contact 169,170. Deletion of acrB confers resistance to CdiA 169, and while it is unclear how AcrB 
contributes to this phenomenon, the transporter is likely to have some role in CdiA entry. 
  
 
FIGURE 1. Schematic of representative structures of multidrug transporters and tripartite 
assemblies. The envelope of Gram-negative bacteria has three principal layers: the outer 
membrane, the inner membrane and the peptidoglycan cell wall in the interstitial periplasm 
between the two membranes. In Gram-negative bacteria, all the drug transporters locate in the 
inner membrane. Structures of representatives of each of the transporter families is presented: 
ABC, MFS, MATE, SMR and RND. The ABC transporters use ATP to drive transport processes, 
and the other families depicted use electrochemical gradients for energy source. The groups 
differ in architectural features, as described in more detail in the main text.  The ligands for the 
MFS, MATE and SMR representatives are indicated. The RND family drug transporters mostly 
assemble with their partner proteins to form tripartite pumps, and these bind substrates at the 
outer leaflet of the inner membrane and periplasm, and efflux them to the cell exterior. By 
contrast, members of the other families of drug transporters usually function as independent 
units in the inner membrane to translocate substrates across the membrane bilayer. It is likely 
that these transporter systems cooperate with RND-type tripartite efflux pumps to deliver 
substrates across the entire cell envelope as part of a larger drug-efflux super-organization. The 
structure of the PACE class of transporters have not yet been experimentally elucidated and are 
therefore not included here. Some ABC family and 14-TMH MFS family transporters could also 
form tripartite pumps and directly transport substrate from the inner leaflet of inner 
membrane and cytoplasm to the exterior. AcrAB-TolC and MacAB-TolC are RND-based and ABC-
based tripartite multidrug efflux pumps, respectively.    
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 2. Transport mechanisms of efflux pumps. 
Figure 2A. Cartoon schematics of the transport mechanism for ABC transporters. Shown is the 
alternating access model with clothes-peg-like movement of protomers, which alternate 
between an inward-facing and outward-facing conformation to translocate substrates across 
the membrane bilayer. The transmembrane domains of ABC transporters comprise the 
substrate-binding pocket and nucleotide-binding domains (NBDs), which bind and hydrolyse 
ATP to drive the transport cycle. The conformational changes are linked to the dimerization and 
dissociation of the NBDs, which is mediated by ATP binding and hydrolysis.  
Figure 2B. A rocker-switch model for the galactoside and H+ symport, exchange and 
counterflow reaction of the MFS group. During the symport cycle, the lactose permease 
symporter LacY binds lactose with high affinity as a result of its protonation (see step 1 for 
influx reaction; step 6 for efflux reaction). The binding of galactoside (see steps 2 or 5) triggers a 
conformational switch from an outward-open (influx) or inward-open (efflux) state to an 
occluded conformation of the dimer (see steps 3 or 4). This is followed by opening up of the 
dimer towards the respective opposite side inward-open (influx) or  outward-open (efflux), the 
release of the substrate and deprotonation of LacY (1 or 6). At this state, LacY adapts an apo-
occluded conformation (see steps 7 or 8).  In case of an exchange or counterflow cycle, LacY 
only undergoes steps 2-5 (yellow area). An analogous process may occur for the drug-exporting 
group of the MFS family. Figure 2C. Cartoon schematics of the transport mechanism of MATE 
transporters. The amino-terminal and carboxy-terminal domains of MATE transporters form a 
V-shaped central cavity. The structures apparently adopt an outward-open state with the lower 
portion of the central cavity situated about halfway through the membrane bilayer. In the 
Neisseria gonorrhoeae NorM, a drug-binding site has been identified in a central cavity situated 
near the membrane-periplasm interface (top panel). The substrate and cation (Na+) interact 
with distinct subsets of amino acids (the three key residues that are involved in Na+-
coordination (corresponding to N. gonorrhoeae NorM Y294, E261 and D377) are indicated), and 
can bind to the protein simultaneously. Therefore, the coupling between the fluxes of Na+ and 
drug is likely to be indirect and mediated by protein conformational changes.  The location of 
the transport substrates rhodamine 6G and ethidium bromide are indicated.  
Substrates bind more deeply within the central cavity of the DinF subfamily member DinF-BH, 
where the interactions are mostly mediated by hydrophobic amino acids. For another DinF 
subfamily member, PfMATE, the drug-binding site is formed exclusively within the N domain 
and is dominated by polar amino acids. The substrate and cation (proton) interact with the 
same amino acids, and compete each other to bind. The coupling between the fluxes of H+ and 
drug is likely direct (not indicated) The location of transport substrates verapamil and Br-NRF 
are indicated.  
 
 
 
 
Figure 3: Transport mechanism and drug pathways for RND transporters.  
Figure 3A. Cartoon schematics of the transport mechanism for RND transporters. The 
representative RND transporter AcrB cycles through three non-equivalent structure states with 
high cooperativity, as depicted in the top panel. The model holds that drugs gain entrance to the 
binding pocket in the periplasmic domain (indicated by dashed lines) in the access (or L) state. 
These can move further into the drug binding pocket in the binding (or T) state, and then are 
extruded into a funnel-shaped ‘canyon’ in the docking domain in the extrusion (or O) state. The 
red lines depict the opening and closing of the entrances to the pockets on the exterior face and 
canyon face. The switch between states is associated with changes in protonation of side chains 
in the transmembrane domain, as depicted in the bottom panel.   
 
Figure 3B. Drug pathways in AcrB. Drug-binding pockets have been identified in AcrB from X-ray 
crystallography and cryoEM studies. The different drug pathways are depicted. The periplasmic 
entry pathway includes the proximal pocket in the L protomer and further transport towards 
the distal binding pocket. Another pathway proposed involves channel 2, defined by the PC1 
and PC2 subdomains in the pore domain and directly guides substrates from the periplasm to 
the proximal pocket. Drugs with higher molecular mass, such as rifampicin and erythromycin, 
favour an access pocket in the L monomer, whereas smaller drugs, such as minocycline and 
doxorubicin, tend to locate to a deep binding pocket within the T monomer. Pump inhibitors, 
such as ABI-PP and MBX3132 (not shown), were shown to penetrate even more deeply into the 
T monomer and insert into a hydrophobic chamber that branches from the deep binding 
pocket. The pockets have multiple sites of interactions and can contact different drugs in very 
different ways, as seen in the overlay of the minocycline and doxorubicin complexes (not 
shown). In an entirely distinct mode of interaction, fusidic acid and other lipophilic carboxylated 
drug locate to a groove at the interface between transmembrane helix 1 (TMH1) and TMH2. 
The poly-specificity of this transporter may be underpinned by the multiplicity of interactions 
within the pocket and dynamic hydration patterns during the transport process.  
 
Figure 4 Drug and inhibitor-binding sites of RND, MFS, and MATE transporters. 
a) Minocycline bound to the periplasmic distal binding pocket of the RND transporter AcrB from 
E. coli (PDB: 4DX5)  
b) MBX-3132 inhibitor bound to the hydrophobic trap region of AcrB (PDB: 5ENQ) 
c) Chloramphenicol bound to the binding area of the MFS transporter MdfA from E. coli (PDB: 
4ZOW) 
d) Rhodamine 6G bound to the binding pocket of the MATE transporter NorM from Neisseria 
gonorrhoeae (PDB: 4HUN) 
The protein main chain is shown in cartoon representation (gray color), drugs or inhibitor are 
shown as sticks and side chains involved in their binding. Color code: side chain C-atoms: 
marine blue, drug C-atoms: slate blue, inhibitor MBX3132 C-atoms: orange. O-atoms: red, N-
atoms: dark blue, S-atom: yellow, Cl-atoms: green.  
 
 
FIGURE 5. Regulation of efflux pumps.  
(A,B) Cartoon schematics of the regulation by two component systems.  (A) Drug binding 
induces a  conformational change in the periplasmic sensor domain. This conformational 
change is transduced downstream to activate the catalytic core, which autophosphorylates at a 
conserved Histidine residue in the dimerization and histidine-phosphotransfer (DHp) domain. 
The phosphoryl group is then transferred from the phosphorylated Histidine residue to an 
aspartic acid residue of the response regulator to activate it.  (B) For the DNA-binding response 
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regulator subfamilies, the activated response regulator generally forms a homodimer, which 
binds to a specific DNA-binding motifs and activates the transcription of target drug transporter 
genes. 
 
Figure 5C. Complex transcriptional regulatory network of efflux pumps. Expression of acrEF and 
acrAB is repressed by AcrS. acrAB is also repressed by the local repressor AcrR. The global 
regulators, Rob, SoxS, and MarA, activate the expression of acrAB, tolC, and micF. Other 
regulators include the histone-like nucleoid structuring protein (H-NS) (repressor) and the SdiA 
global regulator (activator). acrAB and tolC expression is also controlled by the two-component 
regulatory systems EvgAS and/or PhoQP. The micF transcript inhibits the translation of OmpF 
mRNA. ompF transcription is also regulated by several phosphorylated OmpR proteins, which 
bind in hierarchical order to discrete positions on the DNA according to the galloping model 171. 
SoxS and Rob can also stimulate MarA expression. Regulator inactivation can be achieved by 
ligand binding (for example,  antimicrobial agents and metabolites) or  oxidative stress 
induction (see MarR, SoxR, AcrR). Some regulators can also be activated upon ligand-binding 
(for example,  Rob is activated through binding of bile salts or fatty acids). Expression of acrZ is 
co-regulated with the expression of acrAB via MarA, SoxS and Rob 134. (Figure adapted after 4 
and 171). Red lines symbolise transcription repression by the repressors AcrR, AcrS, H-NS, MarR, 
and SoxR. Green lines indicate activation of relevant gene expression by the activators MarA, 
SoxS, SdiA, Rob, EvgS, and PhoP.  
 
Figure 5D. Regulation of efflux pumps by small regulatory RNAs . Small regulatory RNAs (sRNAs) 
regulate antibiotic resistance genes in numerous ways.   Binding of sRNAs to the ribosome-
binding site can repress translation. sRNAs can also induce mRNA degradation by binding to a 
specific cognate site in the transcript and recruit ribonuclease. In addition to repressor 
functions, sRNAs can promote translation by preventing the formation of inhibitory secondary 
structures. Regulatory RNA can also occur in cis-acting elements 128. Antibiotic trigged RNA 
mediated regulation is common in bacteria of human commensal species and pathogens, and 
includes most classes of resistance genes including several predicted classes of multidrug 
antibiotics efflux pumps and exporters 172. 
 
 
Table 1. Examples of clinically relevant MDR efflux pumps. 
Microorganism MDR efflux 
pump family 
Efflux 
system 
Drug resistance 
phenotype  
References 
Acinetobacter 
baumannii 
RND AdeABC Aminoglycosides 
Cefotaxime 
Chloramphenicol 
Erythromycin 
Fluoroquinolones  
Tetracyclines 
Tigecycline  
Trimethoprim 
173 
SMR AbeS  
Chloramphenicol 
Ciprofloxacin 
Erythromycin 
 
 
174 
 
 
Burkholderia sp. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enterobacteriaceae 
RND 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RND 
BpeEF-
OprC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AcrAB-
TolC 
Trimethoprim 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
β-lactams 
Chloramphenicol 
Erythromycin  
Fluoroquinolones 
Novobiocin 
Tetracycline 
Linezolid 
175 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
176 
 
OqxAB*-
TolC 
Cetrimide 
Chloramphenicol 
Fluoroquinolones 
Quinolones 
Nitrofurantoin 
177 
MFS EmrAB-
TolC 
Novobiocin 
Fluoroquinolones 
155 
ABC MacAB-
TolC 
Macrolides 162 
Mycobacterium 
tuberculosis 
MFS EfpA Isoniazid  
Fluoroquinolones 
Rifampicin 
Tetracycline 
Clofazimine 
142,178 
Rv1258c Quinolones 142 
RND MmpS5-
MmpL5 
Isoniazid  
Diarylquinolones 
Rifampicin 
142,179  
SMR Mmr Ofloxacin 
Rifampicin 
142,180 
Pseudomonas 
aeruginosa 
RND MexAB-
OprM 
Aminoglycosides  
Amphenicols  
β-lactams (except 
imipenem) 
Fluoroquinolones 
Macrolides  
Novobiocin 
Sulfonamides  
Tetracyclines 
Thiolactomycin  
Tigecycline 
Trimethoprim  
Reviewed in 181 
 
MexCD-
OprJ 
Chloramphenicol 
Fluoroquinolones 
Macrolides  
Zwitterionic 
cephalosporins 
Tetracyclines  
Trimethoprim 
MexEF-
OprN 
Chloramphenicol 
Fluoroquinolones 
Tetracycline  
Trimethoprim 
MexXY-
OprM 
Aminoglycosides 
Fluoroquinolones 
Macrolides 
Tetracyclines 
Tigecycline 
Zwitterionic 
cephalosporins 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Neisseria 
gonorrhoeae 
SMR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RND 
EmrE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MtrCDE 
Aminoglycosides 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Penicillin (β-lactams) 
Azithromycin 
(macrolides) 
Ceftriaxone 
182 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Reviewed in 181,183  
MtrF Sulphonamides 
MATE NorM Hydrophilic 
fluoroquinolones 
Staphylococcus 
aureus 
MFS NorA Hydrophilic 
fluoroquinolones (e.g. 
norfloxacin, 
ciprofloxacin) 
Reviewed in 184  
QacAB* Biocides and antiseptics, 
e.g. quaternary 
ammonium 
benzalkonium salts, 
chlorhexidine, etc. 
ABC MsrA Macrolides 
Streptogramins 
Streptococcus 
pneumoniae 
MFS PmrA  Fluoroquinolones  
  
Reviewed in 184  
  
ABC PatAB  Fluoroquinolones  
 
  
MATE PdrM Chloramphenicol 
Erythromycin 
 
(*) denotes pumps that are encoded in plasmids, except for Klebsiella pneumoniae. QacAB have 
only been described in S. aureus. 
 
  
 
 
 
 
References   
 
 
1 Alcalde-Rico, M., Hernando-Amado, S., Blanco, P. & Martínez, J. L. Multidrug efflux 
pumps at the crossroad between antibiotic resistance and bacterial virulence. Front. 
Microbiol. 7, 1483 (2016). 
2 Blair, J. M. et al. AcrB drug-binding pocket substitution confers clinically relevant 
resistance and altered substrate specificity. Proceedings of the National Academy of 
Sciences 112, 3511-3516 (2015). 
3 Bergmiller, T. et al. Biased partitioning of the multidrug efflux pump AcrAB-TolC 
underlies long-lived phenotypic heterogeneity. Science 356, 311-315 (2017). 
4 Li, X.-Z., Plésiat, P. & Nikaido, H. The challenge of efflux-mediated antibiotic resistance 
in Gram-negative bacteria. Clin. Microbiol. Rev. 28, 337-418 (2015). 
5 Nichols, R. J. et al. Phenotypic landscape of a bacterial cell. Cell 144, 143-156 (2011). 
6 Lee, A. et al. Interplay between efflux pumps may provide either additive or 
multiplicative effects on drug resistance. J. Bacteriol. 182, 3142-3150 (2000). 
7 Tal, N. & Schuldiner, S. A coordinated network of transporters with overlapping 
specificities provides a robust survival strategy. Proceedings of the National Academy of 
Sciences 106, 9051-9056 (2009). 
8 Hassan, K. A. et al. Transcriptomic and biochemical analyses identify a family of 
chlorhexidine efflux proteins. Proceedings of the National Academy of Sciences 110, 
20254-20259 (2013). 
9 Hassan, K. A., Liu, Q., Henderson, P. J. & Paulsen, I. T. Homologs of the Acinetobacter 
baumannii AceI transporter represent a new family of bacterial multidrug efflux systems. 
MBio 6, e01982-01914 (2015). 
10 Fraimow, H. S. & Tsigrelis, C. Antimicrobial resistance in the intensive care unit: 
mechanisms, epidemiology, and management of specific resistant pathogens. Crit. Care 
Clin. 27, 163-205 (2011). 
11 Viale, P., Giannella, M., Tedeschi, S. & Lewis, R. Treatment of MDR-Gram negative 
infections in the 21st century: a never ending threat for clinicians. Curr. Opin. 
Pharmacol. 24, 30-37 (2015). 
12 Pu, Y. et al. Enhanced efflux activity facilitates drug tolerance in dormant bacterial cells. 
Mol. Cell 62, 284-294 (2016). 
13 Li, N. et al. Structure of a pancreatic ATP-sensitive potassium channel. Cell 168, 101-
110. e110 (2017). 
14 Choudhury, H. G. et al. Structure of an antibacterial peptide ATP-binding cassette 
transporter in a novel outward occluded state. Proceedings of the National Academy of 
Sciences 111, 9145-9150 (2014). 
15 Dawson, R. J. & Locher, K. P. Structure of a bacterial multidrug ABC transporter. Nature 
443, 180 (2006). 
16 Jin, M. S., Oldham, M. L., Zhang, Q. & Chen, J. Crystal structure of the multidrug 
transporter P-glycoprotein from Caenorhabditis elegans. Nature 490, 566 (2012). 
Comment [Editor4]: References 
should be cited sequentially in 
the following order: main text, 
boxes, figures and then tables. 
Currently, the references in the 
table are out of order, and cited 
before the boxes 
17 Johnson, Z. L. & Chen, J. Structural basis of substrate recognition by the multidrug 
resistance protein MRP1. Cell 168, 1075-1085. e1079 (2017). 
18 Kodan, A. et al. Structural basis for gating mechanisms of a eukaryotic P-glycoprotein 
homolog. Proceedings of the National Academy of Sciences 111, 4049-4054 (2014). 
19 Verhalen, B. et al. Energy transduction and alternating access of the mammalian ABC 
transporter P-glycoprotein. Nature 543, 738-741 (2017). 
20 Hürlimann, L. M., Hohl, M. & Seeger, M. A. Split tasks of asymmetric nucleotide-
binding sites in the heterodimeric ABC exporter EfrCD. The FEBS journal 284, 1672-
1687 (2017). 
21 Mishra, S. et al. Conformational dynamics of the nucleotide binding domains and the 
power stroke of a heterodimeric ABC transporter. Elife 3, e02740 (2014). 
22 Khare, D., Oldham, M. L., Orelle, C., Davidson, A. L. & Chen, J. Alternating access in 
maltose transporter mediated by rigid-body rotations. Mol. Cell 33, 528-536 (2009). 
23 Woo, J.-S., Zeltina, A., Goetz, B. A. & Locher, K. P. X-ray structure of the Yersinia 
pestis heme transporter HmuUV. Nature Structural and Molecular Biology 19, 1310 
(2012). 
24 Korkhov, V. M., Mireku, S. A. & Locher, K. P. Structure of AMP-PNP-bound vitamin 
B^ sub 12^ transporter BtuCD-F. Nature 490, 367 (2012). 
25 Mi, W. et al. Structural basis of MsbA-mediated lipopolysaccharide transport. Nature 
(2017). 
26 Bountra, K. et al. Structural basis for antibacterial peptide self-immunity by the bacterial 
ABC transporter McjD. The EMBO journal 36, 3062-3079 (2017). 
27 Venter, H., Shilling, R. A., Velamakanni, S., Balakrishnan, L. & van Veen, H. W. An 
ABC transporter with a secondary-active multidrug translocator domain. Nature 426, 
866-870 (2003). 
28 Singh, H. et al. ATP-dependent substrate transport by the ABC transporter MsbA is 
proton-coupled. Nature communications 7, 12387 (2016). 
29 van Veen, H. W. in ABC transporters-40 Years on     37-51 (Springer, 2016). 
30 Fitzpatrick, A. W. et al. Structure of the macab–tolc abc-type tripartite multidrug efflux 
pump. Nature microbiology 2, 17070 (2017). 
31 Lin, H. T. et al. MacB ABC transporter is a dimer whose ATPase activity and macrolide-
binding capacity are regulated by the membrane fusion protein MacA. J. Biol. Chem. 
284, 1145-1154 (2009). 
32 Okada, U. et al. Crystal structure of tripartite-type ABC transporter MacB from 
Acinetobacter baumannii. Nature Communications 8, 1336 (2017). 
33 Crow, A., Greene, N. P., Kaplan, E. & Koronakis, V. Structure and mechanotransmission 
mechanism of the MacB ABC transporter superfamily. Proceedings of the National 
Academy of Sciences 114, 12572-12577 (2017). 
34 Yamanaka, H., Kobayashi, H., Takahashi, E. & Okamoto, K. MacAB is involved in the 
secretion of Escherichia coli heat-stable enterotoxin II. J. Bacteriol. 190, 7693-7698 
(2008). 
35 Locher, K. P. Mechanistic diversity in ATP-binding cassette (ABC) transporters. Nat. 
Struct. Mol. Biol. 23, 487-493 (2016). 
36 Perez, C. et al. Structure and mechanism of an active lipid-linked oligosaccharide 
flippase. Nature 524, 433 (2015). 
37 Radestock, S. & Forrest, L. R. The alternating-access mechanism of MFS transporters 
arises from inverted-topology repeats. J. Mol. Biol. 407, 698-715 (2011). 
38 Kaback, H. R. A chemiosmotic mechanism of symport. Proceedings of the National 
Academy of Sciences 112, 1259-1264 (2015). 
39 Yin, Y., He, X., Szewczyk, P., Nguyen, T. & Chang, G. Structure of the multidrug 
transporter EmrD from Escherichia coli. Science 312, 741-744 (2006). 
40 Heng, J. et al. Substrate-bound structure of the E. coli multidrug resistance transporter 
MdfA. Cell Res. 25, 1060 (2015). 
41 Jiang, D. et al. Structure of the YajR transporter suggests a transport mechanism based on 
the conserved motif A. Proceedings of the National Academy of Sciences 110, 14664-
14669 (2013). 
42 Wisedchaisri, G., Park, M.-S., Iadanza, M. G., Zheng, H. & Gonen, T. Proton-coupled 
sugar transport in the prototypical major facilitator superfamily protein XylE. Nature 
communications 5, 4521 (2014). 
43 Quistgaard, E. M., Löw, C., Moberg, P., Trésaugues, L. & Nordlund, P. Structural basis 
for substrate transport in the GLUT-homology family of monosaccharide transporters. 
Nature Structural and Molecular Biology 20, 766 (2013). 
44 Zhao, Y. et al. Crystal structure of the E. coli peptide transporter YbgH. Structure 22, 
1152-1160 (2014). 
45 Fluman, N., Ryan, C. M., Whitelegge, J. P. & Bibi, E. Dissection of mechanistic 
principles of a secondary multidrug efflux protein. Mol. Cell 47, 777-787 (2012). 
46 Masureel, M. et al. Protonation drives the conformational switch in the multidrug 
transporter LmrP. Nat. Chem. Biol. 10, 149-155 (2014). 
47 Norimatsu, Y., Hasegawa, K., Shimizu, N. & Toyoshima, C. Protein–phospholipid 
interplay revealed with crystals of a calcium pump. Nature 545, 193 (2017). 
48 Ryan, R. M. & Vandenberg, R. J. Elevating the alternating-access model. Nature 
Structural and Molecular Biology 23, 187 (2016). 
49 Martens, C. et al. Lipids modulate the conformational dynamics of a secondary multidrug 
transporter. Nature Structural and Molecular Biology 23, 744 (2016). 
50 Fluman, N., Adler, J., Rotenberg, S. A., Brown, M. H. & Bibi, E. Export of a single drug 
molecule in two transport cycles by a multidrug efflux pump. Nature communications 5, 
4615 (2014). 
51 Schaedler, T. A. & van Veen, H. W. A flexible cation binding site in the multidrug major 
facilitator superfamily transporter LmrP is associated with variable proton coupling. The 
FASEB Journal 24, 3653-3661 (2010). 
52 Sun, J. et al. Crystal structure of the plant dual-affinity nitrate transporter NRT1. 1. 
Nature 507, 73 (2014). 
53 Federici, L. et al. The crystal structure of the outer membrane protein VceC from the 
bacterial pathogen Vibrio cholerae at 1.8 Å resolution. J. Biol. Chem. 280, 15307-15314 
(2005). 
54 Mousa, J. J. et al. MATE transport of the E. coli-derived genotoxin colibactin. Nature 
microbiology 1, 15009 (2016). 
55 He, X. et al. Structure of a cation-bound multidrug and toxic compound extrusion 
transporter. Nature 467, 991 (2010). 
56 Radchenko, M., Symersky, J., Nie, R. & Lu, M. Structural basis for the blockade of 
MATE multidrug efflux pumps. Nature communications 6, 7995 (2015). 
57 Tanaka, Y. et al. Structural basis for the drug extrusion mechanism by a MATE 
multidrug transporter. Nature 496, 247 (2013). 
58 Ranaweera, I. et al. Structural comparison of bacterial multidrug efflux pumps of the 
major facilitator superfamily. Trends Cell Mol. Biol. 10, 131 (2015). 
59 Radchenko, M., Nie, R. & Lu, M. Disulfide cross-linking of a multidrug and toxic 
compound extrusion transporter impacts multidrug efflux. J. Biol. Chem. 291, 9818-9826 
(2016). 
60 Lu, M. et al. Structures of a Na+-coupled, substrate-bound MATE multidrug transporter. 
Proceedings of the National Academy of Sciences 110, 2099-2104 (2013). 
61 Jin, Y., Nair, A. & van Veen, H. W. Multidrug transport protein NorM from Vibrio 
cholerae simultaneously couples to sodium-and proton-motive force. J. Biol. Chem. 289, 
14624-14632 (2014). 
62 Steed, P. R., Stein, R. A., Mishra, S., Goodman, M. C. & Mchaourab, H. S. Na+–
substrate coupling in the multidrug antiporter NorM probed with a spin-labeled substrate. 
Biochemistry 52, 5790-5799 (2013). 
63 Lu, M., Radchenko, M., Symersky, J., Nie, R. & Guo, Y. Structural insights into H+-
coupled multidrug extrusion by a MATE transporter. Nature Structural and Molecular 
Biology 20, 1310 (2013). 
64 Kuk, A. C., Mashalidis, E. H. & Lee, S.-Y. Crystal structure of the MOP flippase MurJ in 
an inward-facing conformation. Nat. Struct. Mol. Biol. 24, 171 (2017). 
65 Bolla, J. R. et al. Crystal structure of the Neisseria gonorrhoeae MtrD inner membrane 
multidrug efflux pump. PLoS One 9, e97903 (2014). 
66 Eicher, T. et al. Transport of drugs by the multidrug transporter AcrB involves an access 
and a deep binding pocket that are separated by a switch-loop. Proceedings of the 
National Academy of Sciences 109, 5687-5692 (2012). 
67 Murakami, S., Nakashima, R., Yamashita, E. & Yamaguchi, A. Crystal structure of 
bacterial multidrug efflux transporter AcrB. Nature 419, 587-593 (2002). 
68 Nakashima, R., Sakurai, K., Yamasaki, S., Nishino, K. & Yamaguchi, A. Structures of 
the multidrug exporter AcrB reveal a proximal multisite drug-binding pocket. Nature 
480, 565-569 (2011). 
69 Oswald, C., Tam, H.-K. & Pos, K. M. Transport of lipophilic carboxylates is mediated by 
transmembrane helix 2 in multidrug transporter AcrB. Nature communications 7, 13819 
(2016). 
70 Su, C.-C. et al. Structures and transport dynamics of a Campylobacter jejuni multidrug 
efflux pump. Nature Communications 8 (2017). 
71 Gong, X. et al. Structural insights into the Niemann-Pick C1 (NPC1)-mediated 
cholesterol transfer and Ebola infection. Cell 165, 1467-1478 (2016). 
72 Tsukazaki, T. et al. Structure and function of a membrane component SecDF that 
enhances protein export. Nature 474, 235 (2011). 
73 Kumar, N. et al. Crystal structures of the Burkholderia multivorans hopanoid transporter 
HpnN. Proceedings of the National Academy of Sciences 114, 6557-6562 (2017). 
74 Murakami, S., Nakashima, R., Yamashita, E., Matsumoto, T. & Yamaguchi, A. Crystal 
structures of a multidrug transporter reveal a functionally rotating mechanism. Nature 
443, 173-179 (2006). 
75 Seeger, M. A., von Ballmoos, C., Verrey, F. o. & Pos, K. M. Crucial role of Asp408 in 
the proton translocation pathway of multidrug transporter AcrB: evidence from site-
directed mutagenesis and carbodiimide labeling. Biochemistry 48, 5801-5812 (2009). 
76 Eicher, T. et al. Coupling of remote alternating-access transport mechanisms for protons 
and substrates in the multidrug efflux pump AcrB. Elife 3, e03145 (2014). 
77 Seeger, M. A. et al. Structural asymmetry of AcrB trimer suggests a peristaltic pump 
mechanism. Science 313, 1295-1298 (2006). 
78 Kim, H.-S. & Nikaido, H. Different functions of MdtB and MdtC subunits in the 
heterotrimeric efflux transporter MdtB2C complex of Escherichia coli. Biochemistry 51, 
4188-4197 (2012). 
79 Sjuts, H. et al. Molecular basis for inhibition of AcrB multidrug efflux pump by novel 
and powerful pyranopyridine derivatives. Proceedings of the National Academy of 
Sciences 113, 3509-3514 (2016). 
80 Wang, Z. et al. An allosteric transport mechanism for the AcrAB-TolC multidrug efflux 
pump. eLife 6, e24905 (2017). 
81 Nakashima, R. et al. Structural basis for the inhibition of bacterial multidrug exporters. 
Nature 500, 102 (2013). 
82 Hung, L.-W. et al. Crystal structure of AcrB complexed with linezolid at 3.5 Å 
resolution. Journal of structural and functional genomics 14, 71-75 (2013). 
83 Cha, H.-j., Müller, R. T. & Pos, K. M. Switch-loop flexibility affects transport of large 
drugs by the promiscuous AcrB multidrug efflux transporter. Antimicrob. Agents 
Chemother. 58, 4767-4772 (2014). 
84 Yamaguchi, A., Nakashima, R. & Sakurai, K. Structural basis of RND-type multidrug 
exporters. Front. Microbiol. 6 (2015). 
85 Kinana, A. D., Vargiu, A. V. & Nikaido, H. Some ligands enhance the efflux of other 
ligands by the Escherichia coli multidrug pump AcrB. Biochemistry 52, 8342-8351 
(2013). 
86 Vargiu, A. V. et al. Water-mediated interactions enable smooth substrate transport in a 
bacterial efflux pump. Biochimica et Biophysica Acta (BBA)-General Subjects (2018). 
87 Sennhauser, G., Amstutz, P., Briand, C., Storchenegger, O. & Grütter, M. G. Drug export 
pathway of multidrug exporter AcrB revealed by DARPin inhibitors. PLoS Biol. 5, e7 
(2006). 
88 Pos, K. M. Drug transport mechanism of the AcrB efflux pump. Biochimica et 
Biophysica Acta (BBA)-Proteins and Proteomics 1794, 782-793 (2009). 
89 Ababou, A. New insights into the structural and functional involvement of the gate loop 
in AcrB export activity. Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics 
1866, 242-253 (2018). 
90 Zwama, M. et al. Multiple entry pathways within the efflux transporter AcrB contribute 
to multidrug recognition. Nature communications 9, 124 (2018). 
91 Ramaswamy, V. K., Vargiu, A. V., Malloci, G., Dreier, J. & Ruggerone, P. Molecular 
rationale behind the differential substrate specificity of bacterial RND multi-drug 
transporters. Sci. Rep. 7, 8075 (2017). 
92 Schumacher, M. A., Miller, M. C. & Brennan, R. G. Structural mechanism of the 
simultaneous binding of two drugs to a multidrug-binding protein. The EMBO journal 23, 
2923-2930 (2004). 
93 Nikaido, H., Basina, M., Nguyen, V. & Rosenberg, E. Y. Multidrug Efflux Pump AcrAB 
of Salmonella typhimuriumExcretes Only Those β-Lactam Antibiotics Containing 
Lipophilic Side Chains. J. Bacteriol. 180, 4686-4692 (1998). 
94 Neyfakh, A. A. Mystery of multidrug transporters: the answer can be simple. Mol. 
Microbiol. 44, 1123-1130 (2002). 
95 Bay, D. C., Rommens, K. L. & Turner, R. J. Small multidrug resistance proteins: a 
multidrug transporter family that continues to grow. Biochimica et Biophysica Acta 
(BBA)-Biomembranes 1778, 1814-1838 (2008). 
96 Fleishman, S. J. et al. Quasi-symmetry in the cryo-EM structure of EmrE provides the 
key to modeling its transmembrane domain. J. Mol. Biol. 364, 54-67 (2006). 
97 Chen, Y.-J. et al. X-ray structure of EmrE supports dual topology model. Proceedings of 
the National Academy of Sciences 104, 18999-19004 (2007). 
98 Morrison, E. A. et al. Antiparallel EmrE exports drugs by exchanging between 
asymmetric structures. Nature 481, 45 (2012). 
99 Fluman, N., Tobiasson, V. & von Heijne, G. Stable membrane orientations of small dual-
topology membrane proteins. Proceedings of the National Academy of Sciences, 
201706905 (2017). 
100 Woodall, N. B., Yin, Y. & Bowie, J. U. Dual-topology insertion of a dual-topology 
membrane protein. Nature communications 6, 8099 (2015). 
101 Dastvan, R., Fischer, A. W., Mishra, S., Meiler, J. & Mchaourab, H. S. Protonation-
dependent conformational dynamics of the multidrug transporter EmrE. Proceedings of 
the National Academy of Sciences 113, 1220-1225 (2016). 
102 Gayen, A., Leninger, M. & Traaseth, N. J. Protonation of a glutamate residue modulates 
the dynamics of the drug transporter EmrE. Nat. Chem. Biol. 12, 141 (2016). 
103 Lytvynenko, I., Brill, S., Oswald, C. & Pos, K. M. Molecular basis of polyspecificity of 
the small multidrug resistance efflux pump AbeS from Acinetobacter baumannii. J. Mol. 
Biol. 428, 644-657 (2016). 
104 Brill, S., Sade-Falk, O., Elbaz-Alon, Y. & Schuldiner, S. Specificity determinants in 
small multidrug transporters. J. Mol. Biol. 427, 468-477 (2015). 
105 Blair, J. M., Webber, M. A., Baylay, A. J., Ogbolu, D. O. & Piddock, L. J. Molecular 
mechanisms of antibiotic resistance. Nature Reviews Microbiology 13, 42 (2015). 
106 Koteva, K. et al. A vancomycin photoprobe identifies the histidine kinase VanSsc as a 
vancomycin receptor. Nat. Chem. Biol. 6, 327-329 (2010). 
107 Fritz, G. et al. A new way of sensing: need-based activation of antibiotic resistance by a 
flux-sensing mechanism. MBio 6, e00975-00915 (2015). 
108 Piepenbreier, H., Fritz, G. & Gebhard, S. Transporters as information processors in 
bacterial signalling pathways. Mol. Microbiol. 104, 1-15 (2017). 
109 Gushchin, I. et al. Mechanism of transmembrane signaling by sensor histidine kinases. 
Science 356, eaah6345 (2017). 
110 Zschiedrich, C. P., Keidel, V. & Szurmant, H. Molecular mechanisms of two-component 
signal transduction. J. Mol. Biol. 428, 3752-3775 (2016). 
111 Poole, K. et al. Potentiation of aminoglycoside activity in Pseudomonas aeruginosa by 
targeting the AmgRS envelope stress-responsive two-component system. Antimicrob. 
Agents Chemother. 60, 3509-3518 (2016). 
112 Sun, J.-R. et al. Single amino acid substitution Gly186Val in AdeS restores tigecycline 
susceptibility of Acinetobacter baumannii. J. Antimicrob. Chemother. 71, 1488-1492 
(2016). 
113 Marchand, I., Damier-Piolle, L., Courvalin, P. & Lambert, T. Expression of the RND-
type efflux pump AdeABC in Acinetobacter baumannii is regulated by the AdeRS two-
component system. Antimicrob. Agents Chemother. 48, 3298-3304 (2004). 
114 Chang, T.-Y. et al. AdeR protein regulates adeABC expression by binding to a direct-
repeat motif in the intercistronic spacer. Microbiol. Res. 183, 60-67 (2016). 
115 Nowak, J., Schneiders, T., Seifert, H. & Higgins, P. G. The Asp20-to-Asn substitution in 
the response regulator AdeR leads to enhanced efflux activity of AdeB in Acinetobacter 
baumannii. Antimicrob. Agents Chemother. 60, 1085-1090 (2016). 
116 Richmond, G. E. et al. The Acinetobacter baumannii two-component system AdeRS 
regulates genes required for multidrug efflux, biofilm formation, and virulence in a 
strain-specific manner. MBio 7, e00430-00416 (2016). 
117 Nishino, K., Nikaido, E. & Yamaguchi, A. Regulation of multidrug efflux systems 
involved in multidrug and metal resistance of Salmonella enterica serovar Typhimurium. 
J. Bacteriol. 189, 9066-9075 (2007). 
118 Nishino, K. & Yamaguchi, A. Overexpression of the response RegulatorevgA of the two-
component signal transduction system modulates multidrug resistance conferred by 
multidrug resistance transporters. J. Bacteriol. 183, 1455-1458 (2001). 
119 Casino, P., Rubio, V. & Marina, A. Structural insight into partner specificity and 
phosphoryl transfer in two-component signal transduction. Cell 139, 325-336 (2009). 
120 Chen, H. et al. The Pseudomonas aeruginosa multidrug efflux regulator MexR uses an 
oxidation-sensing mechanism. Proceedings of the National Academy of Sciences 105, 
13586-13591 (2008). 
121 Li, M. et al. Crystal structure of the transcriptional regulator AcrR from Escherichia coli. 
J. Mol. Biol. 374, 591-603 (2007). 
122 Wilke, M. S. et al. The crystal structure of MexR from Pseudomonas aeruginosa in 
complex with its antirepressor ArmR. Proceedings of the National Academy of Sciences 
105, 14832-14837 (2008). 
123 Yamada, J. et al. Impact of the RNA chaperone Hfq on multidrug resistance in 
Escherichia coli. J. Antimicrob. Chemother. 65, 853-858 (2010). 
124 Vidyaprakash, E., Abrams, A. J., Shafer, W. M. & Trees, D. L. Whole genome 
sequencing of a large panel of contemporary Neisseria gonorrhoeae clinical isolates 
indicates that a wild-type mtrA gene is common: implications for inducible antimicrobial 
resistance. Antimicrob. Agents Chemother., AAC. 00262-00217 (2017). 
125 Sharma, P. et al. The multiple antibiotic resistance operon of enteric bacteria controls 
DNA repair and outer membrane integrity. Nature Communications 8, 1444 (2017). 
126 Dersch, P., Khan, M. A., Mühlen, S. & Görke, B. Roles of regulatory RNAs for antibiotic 
resistance in bacteria and their potential value as novel drug targets. Front. Microbiol. 8 
(2017). 
127 Lalaouna, D., Eyraud, A., Chabelskaya, S., Felden, B. & Masse, E. Regulatory RNAs 
involved in bacterial antibiotic resistance. PLoS Pathog. 10, e1004299 (2014). 
128 Dar, D. & Sorek, R. Regulation of antibiotic-resistance by non-coding RNAs in bacteria. 
Curr. Opin. Microbiol. 36, 111-117 (2017). 
129 Parker, A. & Gottesman, S. Small RNA regulation of TolC, the outer membrane 
component of bacterial multidrug transporters. J. Bacteriol. 198, 1101-1113 (2016). 
130 Nishino, K., Yamasaki, S., Hayashi-Nishino, M. & Yamaguchi, A. Effect of 
overexpression of small non-coding DsrA RNA on multidrug efflux in Escherichia coli. 
J. Antimicrob. Chemother. 66, 291-296 (2010). 
131 Jackson, L. A., Pan, J.-C., Day, M. W. & Dyer, D. W. Control of RNA stability by NrrF, 
an iron-regulated small RNA in Neisseria gonorrhoeae. J. Bacteriol. 195, 5166-5173 
(2013). 
132 Göpel, Y. & Görke, B. Rewiring two-component signal transduction with small RNAs. 
Curr. Opin. Microbiol. 15, 132-139 (2012). 
133 Storz, G., Wolf, Y. I. & Ramamurthi, K. S. Small proteins can no longer be ignored. 
Annu. Rev. Biochem. 83, 753-777 (2014). 
134 Hobbs, E. C., Yin, X., Paul, B. J., Astarita, J. L. & Storz, G. Conserved small protein 
associates with the multidrug efflux pump AcrB and differentially affects antibiotic 
resistance. Proceedings of the National Academy of Sciences 109, 16696-16701 (2012). 
135 Du, D. et al. Structure of the AcrAB-TolC multidrug efflux pump. Nature 509, 512-515 
(2014). 
136 Young, B. C. et al. Severe infections emerge from commensal bacteria by adaptive 
evolution. eLife 6 (2017). 
137 Balaban, N. Q., Merrin, J., Chait, R., Kowalik, L. & Leibler, S. Bacterial persistence as a 
phenotypic switch. Science 305, 1622-1625 (2004). 
138 Maisonneuve, E., Castro-Camargo, M. & Gerdes, K. (p) ppGpp controls bacterial 
persistence by stochastic induction of toxin-antitoxin activity. Cell 154, 1140-1150 
(2013). 
139 Yang, S. et al. Antibiotic regimen based on population analysis of residing persister cells 
eradicates Staphylococcus epidermidis biofilms. Sci. Rep. 5, 18578 (2015). 
140 Everett, M. J., Jin, Y. F., Ricci, V. & Piddock, L. Contributions of individual mechanisms 
to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and 
animals. Antimicrob. Agents Chemother. 40, 2380-2386 (1996). 
141 Kao, C.-Y. et al. Molecular characterization of antimicrobial susceptibility of Salmonella 
isolates: First identification of a plasmid carrying qnrD or oqxAB in Taiwan. Journal of 
Microbiology, Immunology and Infection 50, 214-223 (2017). 
142 Machado, D. et al. Interplay between Mutations and Efflux in Drug Resistant Clinical 
Isolates of Mycobacterium tuberculosis. Front. Microbiol. 8, 711 (2017). 
143 Zampieri, M. et al. Metabolic constraints on the evolution of antibiotic resistance. Mol. 
Syst. Biol. 13, 917 (2017). 
144 Ohneck, E. A. et al. Overproduction of the MtrCDE efflux pump in Neisseria 
gonorrhoeae produces unexpected changes in cellular transcription patterns. Antimicrob. 
Agents Chemother. 59, 724-726 (2015). 
145 Pacheco, J. O., Alvarez-Ortega, C., Rico, M. A. & Martínez, J. L. Metabolic 
Compensation of Fitness Costs Is a General Outcome for Antibiotic-Resistant 
Pseudomonas aeruginosa Mutants Overexpressing Efflux Pumps. mBio 8, e00500-00517 
(2017). 
146 Stickland, H. G., Davenport, P. W., Lilley, K. S., Griffin, J. L. & Welch, M. Mutation of 
nfxB causes global changes in the physiology and metabolism of Pseudomonas 
aeruginosa. J. Proteome Res. 9, 2957-2967 (2010). 
147 Wang-Kan, X. et al. Lack of AcrB Efflux Function Confers Loss of Virulence on 
Salmonella enterica Serovar Typhimurium. mBio 8, e00968-00917 (2017). 
148 Bailey, A. M. et al. RamA, a member of the AraC/XylS family, influences both virulence 
and efflux in Salmonella enterica serovar Typhimurium. J. Bacteriol. 192, 1607-1616 
(2010). 
149 De Majumdar, S. et al. Elucidation of the RamA regulon in Klebsiella pneumoniae 
reveals a role in LPS regulation. PLoS Pathog. 11, e1004627 (2015). 
150 Yao, H. et al. Emergence of a potent multidrug efflux pump variant that enhances 
Campylobacter resistance to multiple antibiotics. mBio 7, e01543-01516 (2016). 
151 González-Pasayo, R. & Martínez-Romero, E. Multiresistance genes of Rhizobium etli 
CFN42. Mol. Plant. Microbe Interact. 13, 572-577 (2000). 
152 Thanassi, D. G., Cheng, L. W. & Nikaido, H. Active efflux of bile salts by Escherichia 
coli. J. Bacteriol. 179, 2512-2518 (1997). 
153 Elbourne, L. D., Tetu, S. G., Hassan, K. A. & Paulsen, I. T. TransportDB 2.0: a database 
for exploring membrane transporters in sequenced genomes from all domains of life. 
Nucleic Acids Res. 45, D320-D324 (2016). 
154 Lee, E. H. & Shafer, W. M. The farAB-encoded efflux pump mediates resistance of 
gonococci to long-chained antibacterial fatty acids. Mol. Microbiol. 33, 839-845 (1999). 
155 Nishino, K., Latifi, T. & Groisman, E. A. Virulence and drug resistance roles of 
multidrug efflux systems of Salmonella enterica serovar Typhimurium. Mol. Microbiol. 
59, doi:10.1111/j.1365-2958.2005.04940.x (2006). 
156 Buckley, A. M. et al. The AcrAB–TolC efflux system of Salmonella enterica serovar 
Typhimurium plays a role in pathogenesis. Cell. Microbiol. 8, 847-856 (2006). 
157 Bogomolnaya, L. M. et al. The ABC-type efflux pump MacAB protects Salmonella 
enterica serovar typhimurium from oxidative stress. MBio 4, e00630-00613 (2013). 
158 Kunkle, D. E., Bina, X. R. & Bina, J. E. The Vibrio cholerae VexGH RND efflux system 
maintains cellular homeostasis by effluxing vibriobactin. MBio 8, e00126-00117 (2017). 
159 Horiyama, T. & Nishino, K. AcrB, AcrD, and MdtABC multidrug efflux systems are 
involved in enterobactin export in Escherichia coli. PLoS One 9, e108642 (2014). 
160 Sachla, A. J. & Eichenbaum, Z. The GAS PefCD exporter is a MDR system that confers 
resistance to heme and structurally diverse compounds. BMC Microbiol. 16, 68 (2016). 
161 Hagman, K. E. et al. Resistance of Neisseria gonorrhoeae to antimicrobial hydrophobic 
agents is modulated by the mtrRCDE efflux system. Microbiology 141, 611-622 (1995). 
162 Kobayashi, N., Nishino, K. & Yamaguchi, A. Novel Macrolide-Specific ABC-Type 
Efflux Transporter inEscherichia coli. J. Bacteriol. 183, 5639-5644 (2001). 
163 Adams, K. N. et al. Drug tolerance in replicating mycobacteria mediated by a 
macrophage-induced efflux mechanism. Cell 145, 39-53 (2011). 
164 Lee, J. & Zhang, L. The hierarchy quorum sensing network in Pseudomonas aeruginosa. 
Protein & cell 6, 26-41 (2015). 
165 Minagawa, S. et al. RND type efflux pump system MexAB-OprM of Pseudomonas 
aeruginosa selects bacterial languages, 3-oxo-acyl-homoserine lactones, for cell-to-cell 
communication. BMC Microbiol. 12, 70 (2012). 
166 Lamarche, M. G. & Déziel, E. MexEF-OprN efflux pump exports the Pseudomonas 
quinolone signal (PQS) precursor HHQ (4-hydroxy-2-heptylquinoline). PLoS One 6, 
e24310 (2011). 
167 Moore, J. D., Gerdt, J. P., Eibergen, N. R. & Blackwell, H. E. Active efflux influences 
the potency of quorum sensing inhibitors in Pseudomonas aeruginosa. Chembiochem 15, 
435-442 (2014). 
168 Sakhtah, H. et al. The Pseudomonas aeruginosa efflux pump MexGHI-OpmD transports 
a natural phenazine that controls gene expression and biofilm development. Proceedings 
of the National Academy of Sciences 113, E3538-E3547 (2016). 
169 Aoki, S. K. et al. Contact-dependent growth inhibition requires the essential outer 
membrane protein BamA (YaeT) as the receptor and the inner membrane transport 
protein AcrB. Mol. Microbiol. 70, 323-340 (2008). 
170 Ruhe, Z. C., Wallace, A. B., Low, D. A. & Hayes, C. S. Receptor polymorphism restricts 
contact-dependent growth inhibition to members of the same species. MBio 4, e00480-
00413 (2013). 
171 Yoshida, T., Qin, L., Egger, L. A. & Inouye, M. Transcription regulation of ompF and 
ompC by a single transcription factor, OmpR. J. Biol. Chem. 281, 17114-17123 (2006). 
172 Dar, D. et al. Term-seq reveals abundant ribo-regulation of antibiotics resistance in 
bacteria. Science 352, aad9822 (2016). 
173 Lin, M.-F., Lin, Y.-Y., Tu, C.-C. & Lan, C.-Y. Distribution of different efflux pump 
genes in clinical isolates of multidrug-resistant Acinetobacter baumannii and their 
correlation with antimicrobial resistance. Journal of Microbiology, Immunology and 
Infection 50, 224-231 (2017). 
174 Srinivasan, V. B., Rajamohan, G. & Gebreyes, W. A. Role of AbeS, a novel efflux pump 
of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter 
baumannii. Antimicrob. Agents Chemother. 53, 5312-5316 (2009). 
175 Podnecky, N. L., Wuthiekanun, V., Peacock, S. J. & Schweizer, H. P. The BpeEF-OprC 
efflux pump is responsible for widespread trimethoprim resistance in clinical and 
environmental Burkholderia pseudomallei isolates. Antimicrob. Agents Chemother. 57, 
4381-4386 (2013). 
176 Swick, M. C., Morgan-Linnell, S. K., Carlson, K. M. & Zechiedrich, L. Expression of 
multidrug efflux pump genes acrAB-tolC, mdfA, and norE in Escherichia coli clinical 
isolates as a function of fluoroquinolone and multidrug resistance. Antimicrob. Agents 
Chemother. 55, 921-924 (2011). 
177 Hansen, L. H., Jensen, L. B., Sørensen, H. I. & Sørensen, S. J. Substrate specificity of the 
OqxAB multidrug resistance pump in Escherichia coli and selected enteric bacteria. J. 
Antimicrob. Chemother. 60, 145-147 (2007). 
178 Doran, J. L. et al. Mycobacterium tuberculosis efpA encodes an efflux protein of the 
QacA transporter family. Clin. Diagn. Lab. Immunol. 4, 23-32 (1997). 
179 Andries, K. et al. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. 
PLoS One 9, e102135 (2014). 
180 Rodrigues, L., Villellas, C., Bailo, R., Viveiros, M. & Aínsa, J. A. Role of the Mmr efflux 
pump in drug resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 
57, 751-757 (2013). 
181 Dreier, J. & Ruggerone, P. Interaction of antibacterial compounds with RND efflux 
pumps in Pseudomonas aeruginosa. Front. Microbiol. 6, 660 (2015). 
182 Li, X.-Z., Poole, K. & Nikaido, H. Contributions of MexAB-OprM and an EmrE 
homolog to intrinsic resistance of Pseudomonas aeruginosa to aminoglycosides and dyes. 
Antimicrob. Agents Chemother. 47, 27-33 (2003). 
183 Golparian, D., Shafer, W. M., Ohnishi, M. & Unemo, M. Importance of multidrug efflux 
pumps in the antimicrobial resistance property of clinical multidrug-resistant isolates of 
Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 58, 3556-3559 (2014). 
184 Schindler, B. D. & Kaatz, G. W. Multidrug efflux pumps of Gram-positive bacteria. Drug 
Resistance Updates 27, 1-13 (2016). 
 
